<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01847469</url>
  </required_header>
  <id_info>
    <org_study_id>1211011063</org_study_id>
    <secondary_id>01641</secondary_id>
    <nct_id>NCT01847469</nct_id>
  </id_info>
  <brief_title>Zonisamide in Addition to E-CPT-C for Veterans With PTSD and Comorbid Alcohol Dependence</brief_title>
  <official_title>Zonisamide in Addition to Enhanced Cognitive Processing Therapy-C (E-CPT-C) for Veterans With PTSD and Comorbid Alcohol Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, controlled trial with 50 veterans diagnosed with post-traumatic stress
      disorder (PTSD) and comorbid alcohol dependence. Veterans will be randomized to receive
      either zonisamide (400 mg) or placebo for 12 weeks in a double blind fashion. Randomization
      will be done using 3:1 ratio and will be performed by our research pharmacy using a random
      assignment in blocks of 4- 3 will be assigned to active medication and 1 to placebo.
      Medication will be titrated over a 6 week titration phase followed by a 6 week treatment
      phase. All veterans will receive E-CPT-C therapy for the 12 weeks of treatment; E-CPT-C will
      be provided by trained and qualified clinicians with extensive experience providing E-CPT-C.
      Veterans will be recruited primarily through advertisement, but also through the clinical
      facilities at the VA and from other collaborators.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">January 1, 2019</completion_date>
  <primary_completion_date type="Actual">January 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Drinking Days</measure>
    <time_frame>12 weeks</time_frame>
    <description>Using a 90 day Timeline Follow Back (TLFB), the total number of drinking days at baseline and at 12 weeks of treatment were used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Heavy Drinking Days</measure>
    <time_frame>12 weeks</time_frame>
    <description>Timeline Follow Back (TLFB) will be used to document the number of &quot;heavy&quot; drinking days during 12 weeks of treatment. Heavy drinking is defined as greater than or equal to 5 drinks for men and greater than or equal to 4 drinks for women.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinician-Administered PTSD Scale (CAPS) Total Score</measure>
    <time_frame>12 weeks</time_frame>
    <description>The Clinician-Administered PTSD Scale (CAPS) Total Score will be used to measure PTSD symptoms at the end of the 12 week intervention. The CAPS Total Score is a summing of the 17 items that are each scored 0-4- where 0 indicates &quot;none&quot;. The range of Total Scores can be 0 to 136, where 136 would be the highest amount of scored PTSD symptoms.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Alcohol Dependence</condition>
  <condition>Post-Traumatic Stress Disorder (PTSD)</condition>
  <arm_group>
    <arm_group_label>Zonisamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will receive zonisamide for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this arm will receive placebo medication for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Enhanced-Cognitive Processing Therapy-C (E-CPT-C)</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Zonisamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zonisamide</intervention_name>
    <arm_group_label>Zonisamide</arm_group_label>
    <other_name>Zonegran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current alcohol dependence, as determined by a structured clinical interview
             (Structured Clinical Interview for DSM-IV Axis I Disorders) (SCID)

          -  Current PTSD as determined by a structured clinical interview (SCID)

          -  Veterans with current alcohol dependence, with at least one recent episode of heavy
             drinking over the past 14 days.

          -  Medically and neurologically healthy on the basis of history, physical examination,
             EKG, screening laboratories

          -  For women, negative pregnancy test and use of acceptable method of contraception

        Exclusion Criteria:

          -  Females who are pregnant or lactating.

          -  Veterans with a current unstable medical condition such as neurological,
             cardiovascular, endocrine, renal, liver, or thyroid pathology, which in the opinion of
             the physician would preclude the subject from fully cooperating or be of potential
             harm during the course of the study

          -  Veterans who meet current SCID criteria for a major Axis I diagnosis (Bipolar
             Disorders, Schizophrenia and Schizophrenia-type Disorders).

          -  History of substance dependence (other than alcohol, tobacco or cannabis) by DSM-IV
             criteria in the last 90 days.

          -  Veterans taking mood stabilizers and antipsychotic medications for specific
             psychiatric disorders.

          -  Veterans with a history of allergy to zonisamide.

          -  Veterans already receiving CPT.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ismene Petrakis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Connecticut Healthcare System</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 23, 2013</study_first_submitted>
  <study_first_submitted_qc>May 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2013</study_first_posted>
  <results_first_submitted>January 6, 2020</results_first_submitted>
  <results_first_submitted_qc>March 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 16, 2020</results_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Ismene Petrakis</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Alcohol Dependence</keyword>
  <keyword>Post-Traumatic Stress Disorder (PTSD)</keyword>
  <keyword>Zonisamide</keyword>
  <keyword>Cognitive Processing Therapy (CPT)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zonisamide</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 24, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT01847469/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Zonisamide</title>
          <description>Participants in this arm will receive zonisamide for 12 weeks.
Enhanced-Cognitive Processing Therapy-C (E-CPT-C)
Zonisamide</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants in this arm will receive placebo medication for 12 weeks.
Enhanced-Cognitive Processing Therapy-C (E-CPT-C)
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Zonisamide</title>
          <description>Participants in this arm will receive zonisamide for 12 weeks.
Enhanced-Cognitive Processing Therapy-C (E-CPT-C)
Zonisamide</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants in this arm will receive placebo medication for 12 weeks.
Enhanced-Cognitive Processing Therapy-C (E-CPT-C)
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.28" spread="12.94"/>
                    <measurement group_id="B2" value="47.83" spread="11.57"/>
                    <measurement group_id="B3" value="45.17" spread="12.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Drinking Days</title>
        <description>Using a 90 day Timeline Follow Back (TLFB), the total number of drinking days at baseline and at 12 weeks of treatment were used.</description>
        <time_frame>12 weeks</time_frame>
        <population>The intention to treat population was used in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Zonisamide</title>
            <description>Participants in this arm will receive zonisamide for 12 weeks.
Enhanced-Cognitive Processing Therapy-C (E-CPT-C)
Zonisamide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants in this arm will receive placebo medication for 12 weeks.
Enhanced-Cognitive Processing Therapy-C (E-CPT-C)
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Drinking Days</title>
          <description>Using a 90 day Timeline Follow Back (TLFB), the total number of drinking days at baseline and at 12 weeks of treatment were used.</description>
          <population>The intention to treat population was used in the analysis.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.87" spread="5.63"/>
                    <measurement group_id="O2" value="51.00" spread="9.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.44" spread="5.47"/>
                    <measurement group_id="O2" value="17.33" spread="9.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Heavy Drinking Days</title>
        <description>Timeline Follow Back (TLFB) will be used to document the number of &quot;heavy&quot; drinking days during 12 weeks of treatment. Heavy drinking is defined as greater than or equal to 5 drinks for men and greater than or equal to 4 drinks for women.</description>
        <time_frame>12 weeks</time_frame>
        <population>The intention to treat population was used in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Zonisamide</title>
            <description>Participants in this arm will receive zonisamide for 12 weeks.
Enhanced-Cognitive Processing Therapy-C (E-CPT-C)
Zonisamide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants in this arm will receive placebo medication for 12 weeks.
Enhanced-Cognitive Processing Therapy-C (E-CPT-C)
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Heavy Drinking Days</title>
          <description>Timeline Follow Back (TLFB) will be used to document the number of &quot;heavy&quot; drinking days during 12 weeks of treatment. Heavy drinking is defined as greater than or equal to 5 drinks for men and greater than or equal to 4 drinks for women.</description>
          <population>The intention to treat population was used in the analysis.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.94" spread="5.37"/>
                    <measurement group_id="O2" value="31.50" spread="9.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.50" spread="5.22"/>
                    <measurement group_id="O2" value="4.16" spread="9.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinician-Administered PTSD Scale (CAPS) Total Score</title>
        <description>The Clinician-Administered PTSD Scale (CAPS) Total Score will be used to measure PTSD symptoms at the end of the 12 week intervention. The CAPS Total Score is a summing of the 17 items that are each scored 0-4- where 0 indicates &quot;none&quot;. The range of Total Scores can be 0 to 136, where 136 would be the highest amount of scored PTSD symptoms.</description>
        <time_frame>12 weeks</time_frame>
        <population>The intention to treat population was used in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Zonisamide</title>
            <description>Participants in this arm will receive zonisamide for 12 weeks.
Enhanced-Cognitive Processing Therapy-C (E-CPT-C)
Zonisamide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants in this arm will receive placebo medication for 12 weeks.
Enhanced-Cognitive Processing Therapy-C (E-CPT-C)
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Clinician-Administered PTSD Scale (CAPS) Total Score</title>
          <description>The Clinician-Administered PTSD Scale (CAPS) Total Score will be used to measure PTSD symptoms at the end of the 12 week intervention. The CAPS Total Score is a summing of the 17 items that are each scored 0-4- where 0 indicates &quot;none&quot;. The range of Total Scores can be 0 to 136, where 136 would be the highest amount of scored PTSD symptoms.</description>
          <population>The intention to treat population was used in the analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.33" spread="5.49"/>
                    <measurement group_id="O2" value="72.83" spread="9.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.83" spread="6.02"/>
                    <measurement group_id="O2" value="23.80" spread="11.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <desc>Adverse events were collected with a weekly questionnaire of side effects over the 12 week period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Zonisamide</title>
          <description>Participants in this arm will receive zonisamide for 12 weeks.
Enhanced-Cognitive Processing Therapy-C (E-CPT-C)
Zonisamide</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants in this arm will receive placebo medication for 12 weeks.
Enhanced-Cognitive Processing Therapy-C (E-CPT-C)
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <description>Patient taken to emergency care following a fall.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Breast Swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <description>Patient hospitalized due to intoxication and suicidal ideation.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Difficulty Sleeping</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Memory Impairment</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed Mood</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Decreased Libido</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ismene Petrakis</name_or_title>
      <organization>Yale University School of Medicine, VA Connecticut Healthcare System</organization>
      <phone>(203) 932-5711</phone>
      <email>ismene.petrakis@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

